Skip to main content
Erschienen in: Journal of Cancer Survivorship 1/2018

17.10.2017

Body mass index (BMI), postoperative appearance satisfaction, and sexual function in breast cancer survivorship

verfasst von: K. E. Rojas, N. Matthews, C. Raker, M. A. Clark, M. Onstad, A. Stuckey, J. Gass

Erschienen in: Journal of Cancer Survivorship | Ausgabe 1/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose

We sought to explore the correlation between BMI and postoperative sexual function, body image, and breast-specific sensuality before and after breast cancer surgery.

Methods

A cross-sectional survey of patients at least 1 year from surgery employed the Female Sexual Function Index (FSFI) and investigator-generated questions. Patients who underwent lumpectomy (L), mastectomy (M), and mastectomy with reconstruction (MR) were compared across three BMI groups: normal weight, overweight, and obese.

Results

Two hundred fifty-five patients underwent lumpectomy (L, n = 174), mastectomy (M, n = 22), or mastectomy with reconstruction (MR, n = 59). Median age was 57 (range 30–93) and median BMI was 28 (range 19–45). Obese and overweight women reported more appearance dissatisfaction (18.1 and 13.0%) than normal weight women (4.1%) (p = 0.01). Lower satisfaction was associated with increasing BMI within the MR group (p = 0.05). The obese group’s median FSFI score met criteria for sexual dysfunction (25.90, range 11.30–33.10). More overweight women reported their chest played an important role in intimacy before and after surgery, but a postoperative decline in the importance of this role was observed in all groups.

Conclusions

Greater post-treatment BMI is inversely related to postoperative appearance satisfaction, particularly in those undergoing mastectomy with reconstruction. The role of the breast in intimacy is greatest in overweight women, but decreases postoperatively in all BMI groups.

Implications for cancer survivors

Postoperative appearance satisfaction and sexual function seems to be correlated to post-treatment BMI, which highlights the need to encourage perioperative weight management for improved survivorship outcomes.
Literatur
1.
Zurück zum Zitat Surveillance, Epidemiology, and End Results (SEER) Program SEER*Stat Database: Female Breast Cancer, National Cancer Institute, DCCPS, Surveillance Research Program. www.seer.cancer.gov. Accessed 1 Oct 2016. Surveillance, Epidemiology, and End Results (SEER) Program SEER*Stat Database: Female Breast Cancer, National Cancer Institute, DCCPS, Surveillance Research Program. www.​seer.​cancer.​gov. Accessed 1 Oct 2016.
3.
Zurück zum Zitat Hewitt M, Greenfield S, Stovall E, editors. Institute of Medicine and National Research Council. From cancer patient to cancer survivor: lost in transition. Washington, DC: The National Academies Press; 2006. 10.17226/11468. Accessed April 1 2017 Hewitt M, Greenfield S, Stovall E, editors. Institute of Medicine and National Research Council. From cancer patient to cancer survivor: lost in transition. Washington, DC: The National Academies Press; 2006. 10.​17226/​11468. Accessed April 1 2017
4.
Zurück zum Zitat Amichetti M, Caffo O. Quality of life in patients with early stage breast carcinoma treated with conservation surgery and radiotherapy: an Italian monoinstitutional study. Tumori Journal. 2001;87:78–84. Amichetti M, Caffo O. Quality of life in patients with early stage breast carcinoma treated with conservation surgery and radiotherapy: an Italian monoinstitutional study. Tumori Journal. 2001;87:78–84.
5.
Zurück zum Zitat Gorisek B, Krajnc P, Krajnc I. Quality of life and the effect on social status among Slovenian women after breast cancer treatment. J Int Med Res. 2009;37:557–66.CrossRefPubMed Gorisek B, Krajnc P, Krajnc I. Quality of life and the effect on social status among Slovenian women after breast cancer treatment. J Int Med Res. 2009;37:557–66.CrossRefPubMed
6.
Zurück zum Zitat Brandberg Y, Sandelin K, Erikson S, et al. Psychological reactions, quality of life, and body image after bilateral pro-phylactic mastectomy in women at high risk for breast cancer: a prospective 1-year follow-up study. J Clin Oncol. 2008;26:3943–9.CrossRefPubMed Brandberg Y, Sandelin K, Erikson S, et al. Psychological reactions, quality of life, and body image after bilateral pro-phylactic mastectomy in women at high risk for breast cancer: a prospective 1-year follow-up study. J Clin Oncol. 2008;26:3943–9.CrossRefPubMed
7.
Zurück zum Zitat Klaeson K, Berterö C. Sexual identity following breast cancer treatments in premenopausal women. Int J Qual Stud Health Well-being. 2008;3:185–92.CrossRef Klaeson K, Berterö C. Sexual identity following breast cancer treatments in premenopausal women. Int J Qual Stud Health Well-being. 2008;3:185–92.CrossRef
8.
Zurück zum Zitat Krueger D, Cash T, Pruzinsky T. Psychodynamic perspectives on body image. In: Body image: a handbook of theory, research, and clinical practice. New York: Guilford Press; 2004. p. 30–7. Krueger D, Cash T, Pruzinsky T. Psychodynamic perspectives on body image. In: Body image: a handbook of theory, research, and clinical practice. New York: Guilford Press; 2004. p. 30–7.
11.
Zurück zum Zitat Raggio G, Butryn M, Arigo D, et al. Prevalence and correlates of sexual morbidity in long-term breast cancer survivors. Psychol Health. 2014;29:632–50.CrossRefPubMedPubMedCentral Raggio G, Butryn M, Arigo D, et al. Prevalence and correlates of sexual morbidity in long-term breast cancer survivors. Psychol Health. 2014;29:632–50.CrossRefPubMedPubMedCentral
12.
Zurück zum Zitat Hoyt W, Kogan L. Satisfaction with body image and peer relationships for males and females in a college environment. Sex Roles. 2001;45:199–215.CrossRef Hoyt W, Kogan L. Satisfaction with body image and peer relationships for males and females in a college environment. Sex Roles. 2001;45:199–215.CrossRef
13.
Zurück zum Zitat Pujols Y, Meston C, Brooke S. The association between sexual satisfaction and body image in women. J Sex Med. 2010;7:905–16.CrossRefPubMed Pujols Y, Meston C, Brooke S. The association between sexual satisfaction and body image in women. J Sex Med. 2010;7:905–16.CrossRefPubMed
15.
Zurück zum Zitat Rosen R, Brown C, Heiman J, et al. The female sexual function index (FSFI): a multidimensional self-report instrument for the assessment of female sexual function. J Sex Marital Ther. 2000;26(2):191–208.CrossRefPubMed Rosen R, Brown C, Heiman J, et al. The female sexual function index (FSFI): a multidimensional self-report instrument for the assessment of female sexual function. J Sex Marital Ther. 2000;26(2):191–208.CrossRefPubMed
16.
Zurück zum Zitat Baser R, Li Y, Carter J. Psychometric validation of the female sexual function index (FSFI) in cancer survivors. Cancer. 2012;118(18):4606–18.CrossRefPubMed Baser R, Li Y, Carter J. Psychometric validation of the female sexual function index (FSFI) in cancer survivors. Cancer. 2012;118(18):4606–18.CrossRefPubMed
17.
Zurück zum Zitat Mohammedi J. The female sexual function index (FSFI): validation of the Iranian version. Payesh. 2008;7(3):269–78. Mohammedi J. The female sexual function index (FSFI): validation of the Iranian version. Payesh. 2008;7(3):269–78.
18.
Zurück zum Zitat Wiegel M, Meston C, Rosen R. The female sexual function index (FSFI): cross-validation and development of clinical cutoff scores. J Sex Marital Ther. 2005;31:1–20.CrossRefPubMed Wiegel M, Meston C, Rosen R. The female sexual function index (FSFI): cross-validation and development of clinical cutoff scores. J Sex Marital Ther. 2005;31:1–20.CrossRefPubMed
19.
Zurück zum Zitat Rowland J, Meyerowitz B, Crespi C, et al. Addressing intimacy and partner communication after breast cancer: a randomized controlled group intervention. Breast Cancer Res Treat. 2009;118(1):99–111.CrossRefPubMedPubMedCentral Rowland J, Meyerowitz B, Crespi C, et al. Addressing intimacy and partner communication after breast cancer: a randomized controlled group intervention. Breast Cancer Res Treat. 2009;118(1):99–111.CrossRefPubMedPubMedCentral
20.
Zurück zum Zitat Schover L, Baum G, Fuson L, et al. Sexual problems during the first 2 years of adjuvant treatment with aromatase inhibitors. J Sex Med. 2014;11:3102–11.CrossRefPubMedPubMedCentral Schover L, Baum G, Fuson L, et al. Sexual problems during the first 2 years of adjuvant treatment with aromatase inhibitors. J Sex Med. 2014;11:3102–11.CrossRefPubMedPubMedCentral
21.
Zurück zum Zitat Acea Nebril B, Cereijo Garea C, Garcia Novoa A. Cosmetic sequelae after oncoplastic surgery of the breast: classification and factors for prevention. Cir Esp. 2015;2:75–83.CrossRef Acea Nebril B, Cereijo Garea C, Garcia Novoa A. Cosmetic sequelae after oncoplastic surgery of the breast: classification and factors for prevention. Cir Esp. 2015;2:75–83.CrossRef
22.
Zurück zum Zitat Tong W, Baumann D, Villa M, Mittendorg E, Liu J, Robb G, et al. Obese women experience fewer complications after oncoplastic breast repair following partial mastectomy than after immediate total breast reconstruction. Plast Recon Surg. 2016;137(3):777–91.CrossRef Tong W, Baumann D, Villa M, Mittendorg E, Liu J, Robb G, et al. Obese women experience fewer complications after oncoplastic breast repair following partial mastectomy than after immediate total breast reconstruction. Plast Recon Surg. 2016;137(3):777–91.CrossRef
Metadaten
Titel
Body mass index (BMI), postoperative appearance satisfaction, and sexual function in breast cancer survivorship
verfasst von
K. E. Rojas
N. Matthews
C. Raker
M. A. Clark
M. Onstad
A. Stuckey
J. Gass
Publikationsdatum
17.10.2017
Verlag
Springer US
Erschienen in
Journal of Cancer Survivorship / Ausgabe 1/2018
Print ISSN: 1932-2259
Elektronische ISSN: 1932-2267
DOI
https://doi.org/10.1007/s11764-017-0651-y

Weitere Artikel der Ausgabe 1/2018

Journal of Cancer Survivorship 1/2018 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.